IRE ablation plus electroporation-delivered immunotherapy for
This technology combines two cancer-fighting approaches: using precisely targeted electrical pulses to destroy tumor tissue (irreversible electroporation, or IRE), and then delivering immunotherapy drugs directly into or near that ablated zone. The electrical pulses kill cancer cells without heat, which preserves the surrounding tissue structure and releases tumor proteins that can alert the immune system. Adding immunotherapy agents on top of that amplifies the body's natural cancer-fighting response, potentially training the immune system to attack cancer cells elsewhere in the body. The result is a local procedure that may trigger a systemic anti-tumor effect.
What you could build
A procedural protocol and accompanying delivery system for interventional radiologists or oncologists performing IRE tumor ablation, bundled with a defined immunotherapy agent regimen — sold to cancer centers and hospital systems seeking to improve outcomes for inoperable solid tumors.
Who in Virginia should care
Virginia cancer centers (Inova, UVA Health, VCU Massey) and interventional oncology device companies operating in the mid-Atlantic corridor would be natural partners or licensees.
Readiness: Concept
Concept — described but not yet demonstrated. Lab validated — supported by experimental results in the patent. Prototype likely — the text describes a built, working embodiment.
Readiness is inferred from the patent text, not from a lab visit.
The record
- Inventors
- Rafael V. Davalos, John H. Rossmeisl, Paulo A. Garcia
- Filed
- Patent pending — filed July 7, 2023
- Status
- Application
- Publication number
- US20240008911A1
Ready to talk?
Virginia Tech Intellectual Properties handles licensing for this technology.
Prosim summaries are generated from public patent text and are not legal advice.